CASRN 91-22-5 | DTXSID1021798


On this page:

Notice - This site contains archived material(s)

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the Risk Webmaster for assistance. Please use the contact us form if you need additional support.


Quinoline can be derived from petroleum, coal processing, production and use facilities, and shale oil. It is used as an intermediate in the production of various compounds and paints, and as a solvent for resins and terpenes. Acute exposures to quinoline vapors can result in irritation to eyes, nose, and throat , and may cause headaches, dizziness, and nausea in humans (EPA 1985). No noncancer dose-response assessment was performed for either oral or inhalation exposure to quinoline because the database lacked suitable human or animal data. No human epidemiological studies or case reports addressing the potential chronic toxicity or carcinogenicity of quinoline were identified, though enzymes that mediate the metabolic activity of quinoline have been identified in both rats and humans (Reigh et al., 1996). Limited oral carcinogenicity bioassays in various laboratory animals have demonstrated that quinoline exposure can lead to tumor formation relatively quickly (within 12 weeks) in rats and mice. U.S. EPA (1985) classified quinoline as Group C carcinogen (i.e., possible human carcinogen) and concluded that the data sets (rats and mice) were cogent enough to warrant a cancer potency determination under the assumption that quinoline is a human carcinogen. In addition, because quinoline has been shown to increase the incidence of rarely observed vascular tumors of the liver in both sexes of two rodent species, it is considered likely to be carcinogenic in humans in accordance with the proposed EPA carcinogen risk assessment guidelines (U.S. EPA 1996a). The present cancer risk assessment estimates human cancer risk from an oral carcinogenicity bioassay in male rats (Hirao et al. (1976). An oral slope factor of 4.5 (mg/kg/day)-1 for humans was calculated from the animal data.


USEPA. IRIS TOXICOLOGICAL REVIEW OF QUINOLINE [AND IRIS SUMMARY] (EXTERNAL REVIEW DRAFT). U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington Office, Washington, DC, NCEA-S-0883, 2000.

Top of Page

Additional Information

The U.S. Environmental Protection Agency (EPA) is hereby providing for public information a draft Toxicological Review, draft IRIS Summary, and charge to external peer reviewers for EPA's health assessment of quinoline (CAS No. 91-22-5). These documents are provided for public viewing during an external scientific peer review period. While EPA is not soliciting public comments by this action, any scientific views received on the content of the Toxicological Review or IRIS Summary prior to September 31, 2000, will be considered in subsequent drafts.

Top of Page


This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.

Top of Page